Comparison of real-world healthcare resource utilization among advanced therapy-naïve and advanced therapy-experienced patients with ulcerative colitis initiated on ustekinumab or vedolizumab.
Maryia ZhdanavaSumesh KachrooPorpong BoonmakSabree BurbageAditi ShahJill KorsiakPatrick LefebvreCaroline KernerDominic PilonPublished in: Current medical research and opinion (2024)
Among patients with UC with and without advanced therapy experience, higher rates of all-cause and UC-related HRU were observed among those treated with vedolizumab relative to ustekinumab.